Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HALT-C: Long-term Peginterferon alfa-2a in Hepatitis C Non-responders
NCT00006164Phase 3Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Jun 2000
- Primary completion
- Apr 2007
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatitis C (HCV) comparing Peg-interferon alfa-2a 90 mcg/week with Standard of care followup (2 arms). Primary endpoints: Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or Increase in Ishak Hepatic Fibrosis Score at 1400 days, Increase in Ishak Fibrosis Score by 2 Points or More at 4 years and 7 more. Started Jun 2000; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00006164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006164.